UBS Group
DAWN

UBS Group’s Day One Biopharmaceuticals DAWN Stock Holding History

UBS Group’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.4M Buy
2,305,123
+2,134,395
+1,250% +$30.1M 0.01% 1655
2025
Q4 		$1.59M Sell
170,728
-38,989
-19% -$326K ﹤0.01% 5170
2025
Q3 		$1.48M Buy
209,717
+120,242
+134% +$827K ﹤0.01% 5245
2025
Q2 		$582K Sell
89,475
-34,701
-28% -$239K ﹤0.01% 5881
2025
Q1 		$985K Buy
124,176
+59,949
+93% +$646K ﹤0.01% 5299
2024
Q4 		$814K Sell
64,227
-50,410
-44% -$701K ﹤0.01% 5470
2024
Q3 		$1.6M Buy
114,637
+44,554
+64% +$636K ﹤0.01% 4221
2024
Q2 		$966K Sell
70,083
-93,935
-57% -$1.37M ﹤0.01% 4453
2024
Q1 		$2.71M Buy
164,018
+37,378
+30% +$559K ﹤0.01% 3631
2023
Q4 		$1.85M Buy
126,640
+102,759
+430% +$1.25M ﹤0.01% 3914
2023
Q3 		$293K Buy
23,881
+11,338
+90% +$148K ﹤0.01% 5070
2023
Q2 		$150K Sell
12,543
-57,322
-82% -$749K ﹤0.01% 5683
2023
Q1 		$934K Sell
69,865
-59,992
-46% -$1.17M ﹤0.01% 4168
2022
Q4 		$2.79M Buy
129,857
+108,251
+501% +$2.22M ﹤0.01% 3044
2022
Q3 		$432K Buy
21,606
+17,755
+461% +$378K ﹤0.01% 4468
2022
Q2 		$69K Buy
+3,851
New +$39.8K ﹤0.01% 5688
2022
Q1 		– Sell
-6,103
Closed -$103K – 10354
2021
Q4 		$103K Buy
6,103
+6,044
+10,244% +$124K ﹤0.01% 6293
2021
Q3 		$1K Buy
+59
New +$1.41K ﹤0.01% 9166

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

UBS Group's DAWN Position: Q1 2026 in Review

UBS Group increased its Day One Biopharmaceuticals (DAWN) stake by 1,250% in Q1 2026, buying an estimated $30.1M and bringing the position to 2,305,123 shares worth $49.4M. The position accounts for 0.01% of the portfolio, ranked #1655.

UBS Group first reported a position in DAWN in Q3 2021 and has held it in 18 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • UBS Group held 2,305,123 shares of Day One Biopharmaceuticals worth $49.4M as of Q1 2026.
  • UBS Group bought 2,134,395 Day One Biopharmaceuticals shares in Q1 2026, an estimated $30.1M.
  • Day One Biopharmaceuticals made up 0.01% of UBS Group's portfolio in Q1 2026, its #1655 holding.
  • UBS Group first reported a position in Day One Biopharmaceuticals in Q3 2021 and has held it in 18 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.